CompletedPhase 2

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

31 participantsStarted 2000-06-07

Plain-language summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs such as gemcitabine and cisplatin may make tumor cells more sensitive to radiation therapy. Giving combination chemotherapy before surgery or radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving chemotherapy followed by surgery, chemotherapy, and radiation therapy works in treating patients with locally advanced head and neck cancer.

Who can participate

Age range0 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed squamous cell carcinoma of the head and neck, including any of the following subtypes: * Oral cavity * Oropharynx * Hypopharynx * Larynx * Stage III or IV disease * Stage II carcinoma of the larynx, hypopharynx, or base of tongue allowed * Measurable disease * Resectable disease, defined as tumors that are potentially curable by surgery and radiotherapy PATIENT CHARACTERISTICS: * Karnofsky performance status ≥ 60% * ANC ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Creatinine ≤ 1.5 mg/dL OR creatinine clearance \> 60 mL/min * Bilirubin ≤ 1.5 mg/dL * Transaminases and alkaline phosphatase meeting 1 of the following criteria: * ALT or AST ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal * Alkaline phosphatase ≤ 4 times ULN AND ALT and AST normal * ALT or AST \< 1.5 times ULN AND alkaline phosphatase \< 2.5 times ULN * Free of serious infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior malignancy allowed for purposes of determining disease-free or overall survival except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for 5 years * No unstable angina, history of congestive heart failure, or acute myocardial infarction within the past 6 months * No current symptomatic, neurosensory or neuromotor toxicity ≥ grade 2 * No o…

What they're measuring

Overall Response

Timeframe: 30 days after last course of treatment

Progression-free Survival

Timeframe: From date of initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 171 months

Trial details

NCT IDNCT00544414

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-02-14

Results submitted2023-03-10